Cary J. Claiborne
2022 - ADIAL PHARMACEUTICALS
In 2022, Cary J. Claiborne earned a total compensation of $1M as Chief Executive Officer and Member of the Board of Directors at ADIAL PHARMACEUTICALS, a 118% increase compared to previous year.
Compensation breakdown
| Option Awards | $600,862 |
|---|---|
| Salary | $356,722 |
| Other | $58,354 |
| Total | $1,015,938 |
Claiborne received $600.9K in option awards, accounting for 59% of the total pay in 2022.
Claiborne also received $356.7K in salary and $58.4K in other compensation.
Rankings
In 2022, Cary J. Claiborne's compensation ranked 2,987th out of 5,683 executives tracked by ExecPay. In other words, Claiborne earned more than 47.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,987 out of 5,683 | 47th |
Division Manufacturing | 1,673 out of 3,091 | 46th |
Major group Chemicals And Allied Products | 782 out of 1,406 | 44th |
Industry group Drugs | 729 out of 1,307 | 44th |
Industry Pharmaceutical Preparations | 525 out of 949 | 45th |
Source: SEC filing on September 29, 2023.
Claiborne's colleagues
We found three more compensation records of executives who worked with Cary J. Claiborne at ADIAL PHARMACEUTICALS in 2022.